IL28B Diagnostic Test Now Widely Available | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Should You Include Coconut Oil in Your Hep C Wellness Plan?

Back to News Homepage
Next

Seven Tips to Boost HCV Therapy Adherence

IL28B Diagnostic Test Now Widely Available

The Editors at Hepatitis Central
April 20, 2011

Print this page

Available to physicians, other healthcare providers and drug companies for research purposes, Quest Diagnostics now offers a test to identify IL28B – the genetic variant that helps predict responsiveness to interferon-based therapy for Hepatitis C.

Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants

AccuType® IL28B test now available to physicians and for clinical trials research

MADISON, N.J., April 18, 2011 /PRNewswire/ — Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection. Quest Diagnostics is now offering the test to physicians and other healthcare providers in the U.S. and to pharmaceutical companies for use in clinical trials research.

The test was developed through a global non-exclusive license agreement under which Schering Corporation, a Merck affiliate, licensed certain patent rights claiming Interleukin (IL) 28B genetic markers to Quest Diagnostics. These genetic markers have been shown to provide an indicator of potential response to peginterferon alpha-based therapy for HCV. Additional terms were not disclosed.

“Our AccuType IL28B test will give physicians greater insights for treating individual patients infected with the most common form of HCV using standard antiviral therapies,” said Rick L. Pesano, M.D., Ph.D., medical director, infectious diseases, Quest Diagnostics. “AccuType IL28B testing will also help physicians consider alternative therapies, which in the future may include HCV protease inhibitors.”

Continue reading this entire article:
http://www.prnewswire.com/news-releases/quest-diagnostics-launches-hepatitis-c-virus-therapy-test-based-on-il28b-gene-variants-120056609.html

No Comments - be the first!
Share
Share
Previous

Should You Include Coconut Oil in Your Hep C Wellness Plan?

Back to News Homepage
Next

Seven Tips to Boost HCV Therapy Adherence

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.